Table 1.
Demographics of the enrolled study population included in this interim analysis with known seropositivity for SARS-CoV-2 N antigen by group
| Group | 1 | 2 | 3 | 4 | 5 | 6 | |
|---|---|---|---|---|---|---|---|
| 2 μg | 4 μg | 6 μg | 8 μg | 12 μg | Placebo | ||
| N = | 47 | 48 | 46 | 44 | 28 | 32 | |
| Age (years) | Mean | 38.2 | 39.1 | 37.9 | 38.0 | 37.4 | 40.1 |
| SD | 12.5 | 13.2 | 12.6 | 13.2 | 13.5 | 13.5 | |
| Range | (18–60) | (19–59) | (20–59) | (20–59) | (19–59) | (19–60) | |
| 18–40 years, n = | 24 | 24 | 24 | 24 | 17 | 16 | |
| 41–60 years, n = | 23 | 24 | 22 | 20 | 11 | 16 | |
| Male | n (%) | 27 (57) | 25 (52) | 31 (67) | 26 (59) | 17 (61) | 15 (47) |
| Female | 20 (43) | 23 (48) | 15 (33) | 18 (41) | 11 (39) | 17 (53) | |
|
BMI (kg/m2) |
Mean | 23.6 | 24.2 | 24.4 | 23.7 | 23.6 | 23.1 |
| SD | (2.54) | (2.76) | (2.71) | (2.64) | (2.56) | (2.48) | |
| Immune status n (%) | |||||||
| Seropositive | 8 (17) | 8 (17) | 6 (13) | 6 (14) | 4 (14) | 8 (25) | |
| Seronegative | 39 (83) | 40 (83) | 40 (87) | 38 (86) | 24 (86) | 24 (75) | |